Lucid Diagnostics (NASDAQ:LUCD - Get Free Report)'s stock had its "buy" rating restated by research analysts at Needham & Company LLC in a research note issued to investors on Thursday,Benzinga reports. They presently have a $2.50 price target on the stock. Needham & Company LLC's price target would indicate a potential upside of 147.52% from the stock's previous close.
Other equities research analysts have also issued reports about the stock. Canaccord Genuity Group upgraded shares of Lucid Diagnostics to a "strong-buy" rating in a report on Tuesday, August 13th. Ascendiant Capital Markets decreased their target price on shares of Lucid Diagnostics from $7.50 to $7.25 and set a "buy" rating for the company in a research report on Tuesday, September 10th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $3.00 target price on shares of Lucid Diagnostics in a research report on Tuesday, August 13th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $3.94.
Read Our Latest Stock Report on Lucid Diagnostics
Lucid Diagnostics Stock Performance
Lucid Diagnostics stock traded down $0.04 during trading hours on Thursday, hitting $1.01. 506,498 shares of the stock were exchanged, compared to its average volume of 194,140. Lucid Diagnostics has a 12 month low of $0.63 and a 12 month high of $1.58. The business's 50-day moving average is $0.86 and its two-hundred day moving average is $0.85. The stock has a market capitalization of $54.53 million, a P/E ratio of -0.82 and a beta of 1.41.
Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $0.98 million for the quarter. On average, equities analysts predict that Lucid Diagnostics will post -0.82 earnings per share for the current fiscal year.
Institutional Trading of Lucid Diagnostics
A hedge fund recently raised its stake in Lucid Diagnostics stock. Virtu Financial LLC boosted its stake in Lucid Diagnostics Inc. (NASDAQ:LUCD - Free Report) by 66.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,671 shares of the company's stock after purchasing an additional 13,835 shares during the period. Virtu Financial LLC owned about 0.07% of Lucid Diagnostics worth $28,000 at the end of the most recent quarter. 74.01% of the stock is owned by institutional investors and hedge funds.
Lucid Diagnostics Company Profile
(
Get Free Report)
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
See Also
Before you consider Lucid Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lucid Diagnostics wasn't on the list.
While Lucid Diagnostics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
